WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Kylie Jenner and longtime pal Rosalia arrive back at the Mark Hotel in NYC handJudges say they'll draw new Louisiana election map if lawmakers don't by June 3Arrested US soldier awaiting hearing in Russia on theft chargesKylie Jenner and longtime pal Rosalia arrive back at the Mark Hotel in NYC handStormy Daniels admits she hates Trump: Porn star reads his posts calling her 'horseface' in courtMobile home explodes in Minnesota, killing 2 people, sheriff's office saysBoy Scouts of America changes name after 114 years to 'boost inclusion'Stars quickly go from tight series over reigning Cup champ to bigThiago Silva to return to Brazilian club Fluminense after leaving Chelsea at the end of the seasonKylie Jenner and longtime pal Rosalia arrive back at the Mark Hotel in NYC hand
2.271s , 6500.8046875 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,International Intrigue news portal